PMI's U.S. Arrival Makes Us Wonder Where Will BAT's Next Move Land?

BAT by Charlotte Yu, edited by Sophia
Apr.08.2024
PMI's U.S. Arrival Makes Us Wonder Where Will BAT's Next Move Land?
As its longstanding rival prepares to enter the U.S. market, British American Tobacco (BAT) is expected to make strategic moves in response. 2FIRSTS has been closely monitoring the capital market and the company's latest developments to uncover potential actions BAT may take.

In March 2024, during an interview with the Financial Times, Tadeu Marroco, the CEO of British American Tobacco (BAT), dismissed the idea of moving the company's listing from London to New York, calling it "a distraction." This comes after the top ten shareholders who had been pushing for this change have exited their holdings in the tobacco company.

 

Marroco told the Financial Times that changing the listing location "would create a lot of internal disruption," and he did not see the benefits outweighing these negative impacts. He added that there were "many other things" he needed to focus on, including revenue in the United States and new products.

 

His specific mention of the U.S. market led some industry observers to the trial launch of PMI's HNB product IQOS in the country this year. With the arrival of its old rival imminent, what moves will BAT make in the United States? 2FIRSTS has followed up on the capital market and the company's latest dynamics to find any clues.

 

Capital Market: Continuously Valued by Institutional Investors

 

Over the past year, BAT's (LON.BATS) share price has fallen by about 21%, from 2,872.00 GBX (pence) on March 19, 2023, to 2,376.00 GBX on March 19, 2024. However, so far, the top 15 shareholders of BAT still hold 50% of the company's shares, and there have been significant purchases by insiders since March.

 

From publicly disclosed information, hedge funds do not hold much of BAT's shares. Capital Research and Management Company is the largest shareholder, holding 14% of the issued shares. The second-largest shareholder holds about 10% of the circulating shares, while the third-largest holds 8.6%. The large holdings of BAT's shares by these institutions mean they have a significant influence on the company's share price, and such institutional capital investment in the company is usually a huge vote of confidence in its future. Even though the share price has fallen over the past year, its future performance is still widely favored by institutions.

 

菲莫登陆美国在即:资本市场上的英美烟草的下一步棋将落在何方
BAT's shareholders | BAT

 

Relationship with PMI in NGP Field: Thawing the Ice or Continuing the Struggle?

 

The big news in the tobacco industry at the start of 2024 was undoubtedly the patent settlement between PMI and BAT in the heated tobacco field. On February 2, Eastern Time in the United States, both companies announced on their official websites that they had resolved intellectual property disputes related to heated tobacco and electronic cigarette products.

 

BAT is facing the challenge of reversing the decline in cigarette sales in its largest market, the United States. The company's spokesperson stated that this was mainly due to consumers switching to cheaper brands and new types of tobacco. However, BAT has always been lagging behind PMI in the new tobacco market, the latter having achieved great success with its heated tobacco product IQOS.

 

At the same time, Marroco admitted to the media that BAT "started late" in the field of heated tobacco products. This was the first time BAT had "shown weakness" in public. However, he stated that due to the company's market share base in the United States, the company has the capability to catch up in the future. "We have a huge business in the U.S. that can be used to sell (new tobacco products)."

 

BAT's goal is for revenue from alternative products (such as Vuse vapor e-cigarettes and Glo heated tobacco devices) to reach half of total revenue by 2035, eleven years from now. But in 2023, this figure was still at 16%. With PMI resolving patent issues and landing in the United States, if BAT wants to achieve its goal in the next ten years, it must compete head-to-head with PMI in the U.S. market.

 

Increased investment in development shows BAT's determination to "fight to the end" with PMI in the new tobacco field. In March 2023, BAT opened an innovation center at its global R&D headquarters in Southampton, which will play a key role in the company's continued transformation and vision of a "better future." The facility, costing £30 million, provides nine specially designed technical spaces focused on developing nicotine pouches, vapor e-cigarettes, and more. Prior to this, in 2021, BAT had already opened innovation centers in Trieste, Italy, and Shenzhen, China, and invests £300 million annually in R&D for new category products.

 

According to financial reports, BAT spent about £408 million on R&D in 2023, a 26% increase from the £323 million in 2022, mainly invested in harm reduction products. BAT's financial report screenshot | Source: BAT

 

菲莫登陆美国在即:资本市场上的英美烟草的下一步棋将落在何方
BAT financial report|BAT

 

"Cutting Flesh" in Russia, Reducing Holdings in ITC: Capital Retreat and Diversified Investment

 

BAT recently sold shares in ITC worth about 17 billion Indian rupees. Before the sale, BAT held about 29% of the shares in ITC, making it the largest shareholder. BAT had two representatives on the ITC board and was often the only shareholder to raise opinions and questions about the company's operations.

 

CEO Marroco told analysts that because BAT "does not need to hold more than 25% of the shares in ITC to have strategic influence and veto power," the consideration for divestment was mainly based on "cost-effectiveness."

 

However, over the past year, BAT has also stumbled in selling and divesting. In September 2023, BAT, which had been looking to exit the Russian market, finally sold its assets to a consortium led by a local Russian management team, ending a transaction process that lasted for 18 months. However, in a later update on December 6, Marroco stated that BAT had suffered significant losses in the sale of its Russian and Belarusian assets, and that the proceeds BAT received accounted for only a small part of the true value of its businesses in Russia and Belarus.

 

2FIRSTS inquired with BAT's public relations staff in Singapore whether there were any more public divestment plans, but had not received a response by the time of publication. The losses from the sale of Russian and Belarusian businesses can be expected to make British American Tobacco act more cautiously in the following period.

 

In contrast to the contraction trend in tobacco business, BAT's investment arm, Btomorrow Ventures (BTV), is exploring more investment areas. Since its establishment in 2020, BTV has completed 25 investments, with funds mainly flowing to consumer-led innovative technology and sustainable development fields.

 

In addition, in 2023, BAT's subsidiary The Water Street Collective Ltd piloted a series of its own functional beverage brands Ryde in the Australian and Canadian markets; it also signed a joint venture agreement with Charlotte's Web through a subsidiary. 

 

菲莫登陆美国在即:资本市场上的英美烟草的下一步棋将落在何方
Functional beverage Ryde product page screenshot

 

Whether BAT will gradually reduce its reliance on the tobacco sector in the capital market through diversified investments is worth watching.

 

2FIRSTS will continue to follow BAT's movements in the capital market and the market share of new types of products.

Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
British American Tobacco (BAT) Global Travel Retail has expanded the VELO Travellers’ Collection with three new Summer Editions: Mexico, Spain and Sweden. Inspired by destination themes, the new nicotine pouch variants are designed for global travel-retail channels. The launch further strengthens VELO’s positioning as a travel-retail exclusive product collection.
Aug.27
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
According to WNCY on August 24, 2026, some independent vape retailers in Wisconsin say they have faced significant business pressure one year after new vape regulations took effect. Johnny Vapes, a retailer operating in northeast Wisconsin, said its store count fell from seven locations to four, sales declined by about 80%, and roughly 90% of its inventory was affected. Retailers said some consumers have shifted to online purchases or traveled to neighboring Michigan to buy vape products. The case highlights how local regulations can reshape retail operations, inventory management and consumer purchasing patterns.
Aug.28
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
The National Association of Tobacco Outlets is calling for more FDA marketing authorizations, greater transparency in the PMTA process and continued enforcement against unauthorized e-cigarettes, even as its executive director, David Spross, points to recent regulatory developments as signs of progress. At the state level, excise taxes, flavor restrictions and vapor product directories remain major issues for tobacco retailers. By August 2026, 17 states had enacted laws establishing state-managed e-cigarette directories or similar systems.
Innovation
Sep.29 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
DOJO officially launched the BLAST7K Fresh on September 17, 2026, introducing a UK-market prefilled pod product with 6ml of e-liquid and a manufacturer-rated capacity of up to 7,000 puffs. The device features a 1000mAh rechargeable battery, the INSTA-JUICED structure and COREX BLAST dual-mesh technology, while retaining compatibility with existing BLAST pods. The launch comes less than two weeks before the UK's Vaping Products Duty takes effect on October 1. At the new duty rate, 6ml of vaping liquid would correspond to £1.32 in VPD. DOJO has not stated that the product's 6ml format was designed in response to the new duty.
Sep.20
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03